Black Diamond Therapeutic Q3 EPS $(0.45) Beats $(0.46) Estimate; Cash, Cash Equivalents, And Investments Of $144.3M, Expected To Be Sufficient To Fund Operations Into 1H Of 2025
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutic (NASDAQ:BDTX) reported Q3 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.46) by 2.17 percent. This is a 25 percent improvement from the same period last year. The company's cash, cash equivalents, and investments total $144.3M, which is expected to fund operations into the first half of 2025.
November 06, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Black Diamond Therapeutic reported better than expected Q3 losses and has sufficient cash to fund operations into 1H 2025.
Black Diamond Therapeutic reported a smaller loss than expected, which is a positive signal for investors. Additionally, the company's cash position is strong, with enough funds to support operations until the first half of 2025. This financial stability could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100